Use of lentiviral vectors in vaccination.
Antigen expression in vivo
humoral immunity
lentiviral vectors
long-lasting immune memory
non-integrating lentiviral vectors
t-cell immunity
transduction
vaccination
Journal
Expert review of vaccines
ISSN: 1744-8395
Titre abrégé: Expert Rev Vaccines
Pays: England
ID NLM: 101155475
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
pubmed:
9
10
2021
medline:
24
12
2021
entrez:
8
10
2021
Statut:
ppublish
Résumé
Lentiviral vectors have emerged as powerful vectors for vaccination, due to their high efficiency to transduce dendritic cells and to induce long-lasting humoral immunity, CD8 Here, we reviewed the literature, highlighting the relevance of lentiviral vectors in vaccinology. We recapitulated both their virological and immunological aspects of lentiviral vectors. We compared lentiviral vectors to the gold standard viral vaccine vectors, i.e. adenoviral vectors, and updated the latest results in lentiviral vector-based vaccination in preclinical models. Lentiviral vectors are non-replicative, negligibly inflammatory, and not targets of preexisting immunity in human populations. These are major characteristics to consider in vaccine development. The potential of lentiviral vectors to transduce non-dividing cells, including dendritic cells, is determinant in their strong immunogenicity. Notably, lentiviral vectors can be engineered to target antigen expression to specific host cells. The very weak inflammatory properties of these vectors allow their use in mucosal vaccination, with particular interest in infectious diseases that affect the lungs or brain, including COVID-19. Recent results in various preclinical models have reinforced the interest of these vectors in prophylaxis against infectious diseases and in onco-immunotherapy.
Identifiants
pubmed: 34620025
doi: 10.1080/14760584.2021.1988854
doi:
Substances chimiques
Viral Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM